Enveric Biosciences, Inc. (ENVB) Form 8-K — Aug 14, 2026
Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, or $0.76 per basic and diluted share, versus a $2.5 million loss ($11.65 per share) in the year-ago quarter, and ended the period with $8.3 million in cash. That cash balance against the current quarterly burn implies less than a year of runway, keeping future financing and dilution risk in focus for shareholders. The quarter's scientific highlight was lead candidate EB-003: Enveric advanced IND-enabling studies, initiated genotoxicity work, and reported GloSensor assay and in vitro data supporting a non-hallucinogenic, non-photoreactive profile.
Key figures
- Net Income
- -3000000
- Cash Position
- 8300000
- New us patent number
- 12,605,361
- Warrant exercise proceeds
- $1.5 million
- Net non cash expense q2 2026
- $0.3 million
- Gross proceeds from offerings
- $5.0 million
- Potential additional warrant proceeds
- $8.9 million
Price after filing
Close on the filing date to close N calendar days later (from $1.53). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.